DDR1 and neoplasm: Furthermore, the synergistic use of DDR1 degraders with chemotherapy, other targeted therapies, or immunotherapy (including cell-based therapies) could improve treatment efficacy by sensitizing tumors to therapeutic agents, disrupting the tumor microenvironment, and reinstating immune responses.